Tuesday, May 17th, 2016 - RnR Market Research

Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies for NASH. Therefore, there is a worldwide need for new therapies to treat the global epidemic of NASH and the cost to society will be huge if it is not addressed in the upcoming years! Besides, scarcity of treatment options, there is also an urgent unmet need to develop biomarkers that facilitate the diagnosis, identification of populations at risk, assessment of disease progression or regression, and/or response to treatment. The potential market is gigantic with analysts predicting north of $35bn by 2025!

Complete report “Rising Stars Outlook 2016 :New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH)” is available at http://www.rnrmarketresearch.com/rising-stars-outlook-2016-new-emergence-of-potential-tx-dx-options-could-transform-the-current-landscape-for-liver-diseases-nash-market-report.html.

Many small players are currently developing drugs on their own and with such a large unmet need, market potential and disease heterogeneity, we expect many Giants to join this race and thus, we can see more Licensing deals/ M&A activity on the horizon! In light of recent developments in NASH, we have added few in-depth coverage of companies which either target early-stage NASH, late-stage NASH, or large pts pool-NAFLD in our Outlook this year.

Companies Mentioned: Conatus Pharmaceuticals (CNAT), Galectin Therapeutics (GALT), Galmed Pharmaceuticals (GLMD), Genfit SA (GNFT), Intercept Pharmaceuticals (ICPT) and Tobira Therapeutics (TBRA)

Rising Stars Outlook 2016: New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH) Table of Contents

  1. Conatus Pharmaceuticals (CNAT)
  2. Galectin Therapeutics (GALT)
  3. Galmed Pharmaceuticals (GLMD)-Aramchol: A Differentiated Approach, Targeting Early NASH and Potentially, NAFL Pts
  4. Genfit SA (GNFT)
  5. Intercept Pharmaceuticals (ICPT)
  6. Tobira Therapeutics

List of Tables

KEY MILESTONES (CNAT)
Gelectin Therapeutics : Key Milestone Table
Table1
Conatus Pharma
PHIIB, ENCORE PROGRAM IN DIFFERENT ETIOLOGIES & STAGES
Table 2
Conatus Pharma
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
Table 1
Galectin Therapeutics
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
Galmed - Key Milestone Table
Table 1
Galmed Pharmaceuticals
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
Table 1
Genfit SA
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
Intercept : Key Milestone Table
Table 1
Intercept Pharmaceuticals
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
Table 1
Tobira Therapeutics
DRUGS IN DEVELOPMENT FOR NASH
Table 2
Tobira Therapeutics
CENICRIVIROC (CVC): PHIIB DATA IN HIV PTS - FAVORABLE 48-WEEK SAFETY (COMBINED WITH FTC/TDF)

Purchase a Copy of Report at http://www.rnrmarketresearch.com/contacts/purchase?rname=516348.

List of Figures

Figure 1
Conatus Pharma
EMRICASAN: DATA FROM PHII, LIVER CIRRHOSIS TRIAL (3-MONTHS)
Figure 2
Conatus Pharma
EMRICASAN: MEDICAL NEED AND MARKET OPPORTUNITIES
Figure 3
Conatus Pharma
EMRICASAN: A POTENT INHIBITOR OF APOPTOTIC AND INFLAMMATORY CASPASES
Figure 4
Conatus Pharma
EMRICASAN: PHASE II, LIVER CIRRHOSIS TRIAL (3 MONTHS)
Figure 5
Conatus Pharma
EMRICASAN: PHASE II DATA @ EASL, 2015
Figure 6
Conatus Pharma
EMRICASAN: PHASE II DATA @ AASLD, 2015
Figure 1
Galectin Therapeutics
ROLE OF GALECTIN-3 IN PATHOPHYSIOLOGY OF NASH AND FIBROGENESIS
Figure 2
Galectin Therapeutics
PHASE II TRIAL DESIGNS: NASH-CX (W/ CIRRHOSIS) & NASH-FX (W/ ADVANCED FIBROSIS
Figure 3
Galectin Therapeutics
GR-MD-02: PHI STUDY - SERUM BIOMARKERS EVALUATION
Figure 4
Galectin Therapeutics
GR-MD-02: PRECLINICAL DATA - TX EFFECT ON NASH WITH FIBROSIS
Figure
Galectin Therapeutics
PIPELINE PORTFOLIO
Figure 1
Galmed Pharmaceuticals
ARAMCHOL: PHASE IIA DATA - RELATIVE CHANGE IN LIVER-FAT CONCENTRATION
Figure 2
Galmed Pharmaceuticals
ARAMCHOL: DIFFERENTIATED MODE OF ACTION
Figure 3
Galmed Pharmaceuticals
ARAMCHOL: CLINICAL TRIALS AND ITS ENDPOINTS
Figure 4
Galmed Pharmaceuticals
PHIIA RESULTS: CHANGES IN CHOLESTEROL AND SERUM ADIPONECTIN LEVELS
Figure 5
Galmed Pharmaceuticals
CHANGES IN THE LEVELS OF CHOLESTEROL CRYSTALLIZATION AFTER THE ADDITION OF ARAMCHOL
Figure 1
Genfit SA
GOLDEN-505: COMPARISON WITH OTHER PHII STUDIES
Figure 2
Genfit SA
GOLDEN-505: COMPARISON WITH OTHER PHII STUDIES
Figure 3
Genfit SA
ELAFIBRANOR: PPAR??? REGULATES NUMEROUS PATHWAYS ESSENTIAL IN NASH

And more.

Explore other reports on MP Advisors at http://www.rnrmarketresearch.com/publisher/MP-Advisors.html.

File Library

Contact Profile

RnR Market Research


About Us:  

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us: 

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed


Ritesh Tiwari
P: + 1 888 391 5441
W: www.rnrmarketresearch.com/

Keywords

NASH, Liver Diseases, Non-Alcoholic SteatoHepatitis

Categories

Newsrooms

Sharing

More Formats